FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug Administration U.S. Food and Drug Administration Center for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 
 

Warning Letters and Untitled Letters
to Pharmaceutical Companies
2007

These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office. This page only covers Division of Drug Marketing and Communications and Headquarters Warning Letters.  For District Office Warning Letters see the Main FDA FOI Warning Letters Page.    Some of the letters have been redacted or edited to remove confidential information. Click on the month to view the letters in Adobe Acrobat format. [more...]

[2008] 2007 [2006] [2005] [2004] [2003] [2002] [2001] [2000] [1999] [1998] [1997]
December 2007
Product/Issue Company/Individual Division Released Posted

Effexor XR (venlafaxine HCl) Tablets (Warning Letter)

Wyeth Pharmaceuticals Inc. DDMAC 12/10/2007 12/14/2007

Lindane Shampoo (Warning Letter)

Morton Grove Pharmaceuticals, Inc. DDMAC 12/14/2007 1/9/2008
November 2007
Product/Issue Company/Individual Division Released Posted

Natrecor

Scios Inc DDMAC 11/6/2007 11/7/2007

TYKERB (lapatinib) Tablets

GlaxoSmithKline DDMAC 11/21/2007 11/26/2007
October 2007
Product/Issue Company/Individual Division Released Posted
Site Inspection (Warning Letter) Northeast General Pharmaceutical Factory DMPQ 10/31/2007 11/1/2007
BMIS Inspection (Warning Letter) Surendra Chaganti, M.D. DSI 10/26/2007 2/15/2008

BMIS Inspection (Warning Letter)

Sanofi-Aventis U.S. DSI 10/23/2007 10/24/2007
September 2007
Product/Issue Company/Individual Division Released Posted

Cymbalta (duloxetine hydrochloride)

Eli Lilly & Company DDMAC 9/21/2007 10/2/2007
BMIS Inspection (Warning Letter) Robert J. Amato, D.O. DSI 9/18/2007 4/15/2008

Site Inspection (Warning Letter)

Kunshan Chemical & Pharmaceutical Company DMPQ 9/6/2007 9/20/2007
August 2007
Product/Issue Company/Individual Division Released Posted

Exelon (rivastigmine tartrate) Capsules and Oral Solution (Warning Letter)

Novartis Pharmaceuticals Corporation DDMAC 8/8/2007 8/14/2007
July 2007
Product/Issue Company/Individual Division Released Posted

BMIS Inspection (Warning Letter)

David Linden, M.D. DDMAC 7/3/2007 8/10/2007

Geodon (ziprasidone mesylate) for Injection

Pfizer Inc. DDMAC 7/16/2007 8/13/2007

Solaraze (dicolofenac sodium)

Doak Dermatologics DDMAC 7/17/2007 7/18/2007
June 2007
Product/Issue Company/Individual Division Released Posted

BMIS Inspection (Warning Letter)

Frank A. Wingrove, D.D.S DSI 6/22/2007 8/10/2007

BMIS Inspection (Warning Letter)

Sitek Research Laboratories DSI 6/25/2007 7/6/2007
May 2007
Product/Issue Company/Individual Division Released Posted

Abelcet (Amphotericin B Lipid Complex Injection) (Warning Letter)

Enzon Pharmaceuticals DDMAC 5/21/2007 5/24/2007

Acular LS (ketorlac tromethamine) ophthalmic solution (Warning Letter)

Allergan, Inc. DDMAC 5/25/2007 5/30/2007
BMIS Inspection (Warning Letter) David H. Vesole, M.D., Ph.D. DSI 5/30/2007 6/11/2007

Clindesse (clindamycin phosphate) vaginal cream

KV Pharmaceutical DDMAC 5/17/2007 5/22/2007

Flonase (fluticasone propionate) Nasal Spray

GlaxoSmithKline DDMAC 5/7/2007 5/9/2007

Nasonex (mometasone furoate monohydrate)

Schering DDMAC 5/7/2007 5/9/2007
April 2007
Product/Issue Company/Individual Division Released Posted

Ciprodex (ciprofloxacin) sterile otic suspension (Warning Letter)

Alcon Laboratories DDMAC 4/20/2007 4/24/2007

Levulan Kerastick (aminolevulinic acid HCl) (Warning Letter)

DUSA Pharmaceuticals, Inc. DDMAC 4/20/2007 4/26/2007
March 2007
Product/Issue Company/Individual Division Released Posted

Rozerem (ramelteon) tablets

Takeda Pharmaceuticals North America DDMAC 3/5/2007 3/8/2007
February 2007
Product/Issue Company/Individual Division Released Posted
BMIS Inspection (Warning Letter) Jerry M. Herron, M.D. DSI 2/13/2007 4/23/2007
BMIS Inspection (Warning Letter) Robert Michael Murray, M.D. DSI 2/28/2007 4/23/2007
BMIS Inspection (Warning Letter) Hollis J.C. Underwood, M.D. DSI 2/15/2007 4/23/2007
Marketing an unapproved new drug - ergotamine tartrate Actavis Totowa LLC DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Anabolic Laboratories DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Bio Pharm Inc. DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Breckenridge Pharmaceutical Inc. DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Centrix Pharmaceutical Inc. DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate DRX Pharmaceutical Consultants Inc. DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate DSC Laboratories DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Excellium Pharmaceutical Inc. DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Ferndale Laboratories Inc. DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Harvard Drug Group DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate IVAX Pharmaceuticals Inc. DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Kaiser Foundation Hosptials DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Lini Inc. DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Murfreesboro Pharmaceutical Nursing Supply DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Nucare Pharmaceuticals Inc. DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Qualitest Pharmaceuticals, Inc. DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Sandoz Inc. DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate SDA Laboratories DLNDC 2/26/2006 3/20/2007
Marketing an unapproved new drug - ergotamine tartrate United Research Laboratories Inc. and Mutual Pharmaceutical Company DLNDC 2/26/2007 3/1/2007
Marketing an unapproved new drug - ergotamine tartrate Vintage Pharmaceuticals Inc. DLNDC 2/26/2007 3/1/2007
Site Inspection (Warning Letter) Niagra Pharmaceuticals DMPQ 2/23/2007 3/1/2007

Provigil (Warning Letter)

Cephalon DDMAC 2/27/2007 3/1/2007
January 2007
Product/Issue Company/Individual Division Released Posted
BMIS Inspection (Warning Letter) Avlon Industries Compliance 1/19/2007 1/31/2007
BMIS Inspection (Warning Letter) Lawrence S. Kim, M.D. DSI 1/16/2007 4/15/2008

Gliadel Wafer (polifeprosan 20 with carmustine implant)

MGI PHARMA, Inc. DDMAC 1/29/2007 1/31/2007
Evoxac Capsules (cevimeline hydrochloride) (Warning Letter) Daiichi Sankyo, Inc. DDMAC 1/12/2007 1/19/2007
Pharmacy Compounding of Domperidone
(Warning Letter)
Kalchem International, Inc. DNDLC 1/8/2007 1/9/2008

Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the recipient of the letter that may have changed the regulatory status of the issues discussed in the letter.  If you wish to obtain available additional information on the current status of an issue in a particular warning letter or notice of violation on this website, please contact the Agency or the recipient of the letter directly.  Inquiries to FDA should be sent to:

Food and Drug Administration
Freedom of Information Staff (HFI-35)
5600 Fishers Lane, Rockville, MD 20857

Instructions for how to submit an FOI request can be found on the FDA FOI Page.

The letters are arranged in chronological order by month.  Click on the product name to view the letters in Adobe Acrobat (PDF) format. Go here for further information about Adobe Acrobat and download instructions.

Also see the "Cyber" Letters.

top arrow Back to Top     back arrow Index

Date created: January 11, 2006; updated July 8, 2008

horizonal rule